Influence of the COVID-19 Pandemic on Quality of Life of Patients with Parkinson’s Disease
Table 4
Comparison of PDQ-39 outcomes between during and after epidemic prevention and control in patients who changed routine medication and those who did not.
Variables
During epidemic prevention and control
After epidemic prevention and control
t value
Sig
Patients who changed routine medication (n = 86)
Mobility
20.80 ± 3.41
15.74 ± 3.37
17.330
< 0.001
ADL
13.03 ± 2.29
10.41 ± 2.44
9.172
< 0.001
Emotional well-being
12.80 ± 1.79
9.84 ± 2.44
12.270
< 0.001
Stigma
8.81 ± 1.85
7.26 ± 1.98
8.724
< 0.001
Social support
6.48 ± 1.45
6.20 ± 1.80
1.716
0.090
Cognition
8.62 ± 1.98
6.85 ± 2.06
9.107
< 0.001
Communication
6.10 ± 1.62
4.99 ± 1.74
5.095
< 0.001
Bodily discomfort
6.56 ± 1.65
4.13 ± 1.58
13.061
< 0.001
Total score
83.21 ± 8.43
65.41 ± 8.77
24.602
< 0.001
Patients who did not change routine medication (n = 22)
